Loading...
| A03048 | Pages: NA | Dec 2021 | 4594 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Hyoscine Market
Request Now !Hyoscine, also referred as scopolamine, is utilized as a medicine to treat motion sickness, gastrointestinal spasms, vomiting, and postoperative nausea. In addition, it is utilized sometimes before surgery to decrease saliva. Hyoscine belongs to antimuscarinic family and works by blocking some acetylcholine effects within the nervous system. Its effect begins after 20 minutes of injection and lasts up to 8 hours. The medicine can be taken by oral means or through a skin patch. Intake of this medicine is not recommended for people suffering from bowel obstruction or glaucoma.
Rise in consumer awareness towards hyoscine as an effective medicine against motion sickness is the primary factor that drive the growth of the hyoscine market. Moreover, increase in travelling, which may cause nausea, vomiting, and sickness and growth in number of surgeries supplement the market growth. However, use of transdermal hyoscine patches can cause several side effects such as blurred vision, drowsiness, and diluted pupils, which hinder the market growth. In addition, stringent regulations associated with manufacturing & marketing of hyoscine products and rise in number of cases with adverse withdrawal symptoms for transdermal hyoscine patches restrain the market growth. Increase in usage of transdermal hyoscine patches in surgeries & post-operative recovery and rise in emphasis on community healthcare in developing countries are expected to provide potential opportunities for market expansion.
The report segments the hyoscine market on the basis of type, application, and geography. Based on type, the market is divided into hyoscine butylbromide and hyoscine hydrobromide. By application, it is categorized into oral, injections, and patches. Geographical breakdown of the market includes North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive Competitive Analysis And Profiles Of Major Market Players Provided In The Report Are As Follows:
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 GLOBAL HYOSCINE MARKET, BY TYPE
4.1. OVERVIEW
4.1.1. Key market trends
4.1.2. Key growth factors and opportunities
4.1.3. Market size and forecast
4.2. HYOSCINE BUTYLBROMIDE
4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.3. HYOSCINE HYDROBROMIDE
4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
CHAPTER 5 GLOBAL HYOSCINE MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ORAL
5.2.1. Key market trends
5.2.2. Growth factors and opportunities
5.2.3. Market size and forecast
5.3. INJECTIONS
5.3.1. Key market trends
5.3.2. Growth factors and opportunities
5.3.3. Market size and forecast
5.4. PATCHES
5.4.1. Key market trends
5.4.2. Growth factors and opportunities
5.4.3. Market size and forecast
CHAPTER 6 GLOBAL HYOSCINE MARKET, BY GEOGRAPHY
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. By Type
6.2.3.2. By Application
6.2.4. U.S.
6.2.4.1. Market size and forecast, by Application
6.2.5. Canada
6.2.5.1. Market size and forecast, by Application
6.2.6. Mexico
6.2.6.1. Market size and forecast, by Application
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. By Type
6.3.3.2. By Application
6.3.4. UK
6.3.4.1. Market size and forecast, by Application
6.3.5. Germany
6.3.5.1. Market size and forecast, by Application
6.3.6. France
6.3.6.1. Market size and forecast, by Application
6.3.7. Spain
6.3.7.1. Market size and forecast, by Application
6.3.8. Italy
6.3.8.1. Market size and forecast, by Application
6.3.9. Rest of Europe
6.3.9.1. Market size and forecast, by Application
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. By Type
6.4.3.2. By Application
6.4.4. China
6.4.4.1. Market size and forecast, by Application
6.4.5. Japan
6.4.5.1. Market size and forecast, by Application
6.4.6. India
6.4.6.1. Market size and forecast, by Application
6.4.7. Australia
6.4.7.1. Market size and forecast, by Application
6.4.8. South Korea
6.4.8.1. Market size and forecast, by Application
6.4.9. Rest of Asia-Pacific
6.4.9.1. Market size and forecast, by Application
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. By Type
6.5.3.2. By Application
6.5.4. Brazil
6.5.4.1. Market size and forecast, by Application
6.5.5. South Africa
6.5.5.1. Market size and forecast, by Application
6.5.6. Saudi Arabia
6.5.6.1. Market size and forecast, by Application
6.5.7. Rest of LAMEA
6.5.7.1. Market size and forecast, by Application
CHAPTER 7 COMPANY PROFILES
7.1. ALCHEM INTERNATIONAL LTD.
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. ALKALOIDS CORPORATION
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. BAXTER INTERNATIONAL INC.
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. CALEB PHARMACEUTICALS, INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. CENTROFLORA CMS S.À R.L.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. GLAXOSMITHKLINE PLC
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. GUANGZHOU HANFANG PHARMACEUTICAL CO., LTD.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. MYUNGMOON PHARMA CO., LTD.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. NOVARTIS INTERNATIONAL AG
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. PERRIGO COMPANY PLC
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
